NCT02196064View on ClinicalTrials.gov

"Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the The HEPAVIR HEPATIC SAFETY Cohort."

CompletedOBSERVATIONAL

Enrollment

519

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Human Immunodeficiency Virus (HIV) Hepatitis C Virus (HCV) Coinfected Subjects

Trial Locations (1)

41092

Fundación Pública Andaluza Progreso y Salud, Seville

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Fundación Pública Andaluza Progreso y Salud

OTHER

NCT02196064 - "Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the The HEPAVIR HEPATIC SAFETY Cohort." | Biotech Hunter | Biotech Hunter